ROSSARI, FEDERICO
 Distribuzione geografica
Continente #
NA - Nord America 1.998
EU - Europa 1.301
AS - Asia 985
SA - Sud America 172
Continente sconosciuto - Info sul continente non disponibili 117
AF - Africa 18
OC - Oceania 2
Totale 4.593
Nazione #
US - Stati Uniti d'America 1.895
RU - Federazione Russa 658
IT - Italia 384
SG - Singapore 361
CN - Cina 246
BR - Brasile 138
BD - Bangladesh 113
HK - Hong Kong 79
VN - Vietnam 78
CA - Canada 52
GB - Regno Unito 51
DE - Germania 49
FR - Francia 44
IN - India 29
NL - Olanda 28
JP - Giappone 22
MX - Messico 18
AR - Argentina 14
PL - Polonia 12
SE - Svezia 12
ES - Italia 9
FI - Finlandia 9
AT - Austria 7
CO - Colombia 7
ZA - Sudafrica 7
CR - Costa Rica 6
LT - Lituania 6
PK - Pakistan 6
SA - Arabia Saudita 6
CH - Svizzera 5
HN - Honduras 5
ID - Indonesia 5
JM - Giamaica 5
MY - Malesia 5
NI - Nicaragua 5
TR - Turchia 5
BE - Belgio 4
GR - Grecia 4
GT - Guatemala 4
IQ - Iraq 4
MA - Marocco 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
EG - Egitto 3
IE - Irlanda 3
IR - Iran 3
NP - Nepal 3
PR - Porto Rico 3
SI - Slovenia 3
SV - El Salvador 3
UA - Ucraina 3
VE - Venezuela 3
AU - Australia 2
EC - Ecuador 2
KR - Corea 2
LB - Libano 2
PE - Perù 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CG - Congo 1
CL - Cile 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MV - Maldive 1
PH - Filippine 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
UY - Uruguay 1
Totale 4.479
Città #
Dallas 844
Singapore 235
Ashburn 142
Moscow 120
San Jose 112
Hong Kong 75
Milan 75
Beijing 62
New York 62
Council Bluffs 54
Los Angeles 48
Santa Clara 37
Phoenix 29
Ho Chi Minh City 28
Rome 28
Orem 24
North Bergen 23
Lauterbourg 21
Naples 21
Munich 18
São Paulo 18
Tokyo 18
Hanoi 16
Montreal 15
Toronto 15
Boardman 14
Hefei 14
Shanghai 14
Poplar 13
Atlanta 12
Boston 12
Chicago 12
Manchester 12
Denver 11
London 11
Frankfurt am Main 10
Mexico City 10
Warsaw 10
Bologna 9
Brooklyn 9
Monza 8
Cesano Boscone 7
Chennai 7
Guangzhou 7
Palermo 7
Amsterdam 6
Bacoli 6
Bari 6
Berlin 6
Biên Hòa 6
Charlotte 6
Houston 6
Newark 6
Nuremberg 6
Secaucus 6
Stockholm 6
Dhaka 5
Genoa 5
Helsinki 5
Managua 5
Miano 5
Verona 5
Washington 5
West Palm Beach 5
Belo Horizonte 4
Buffalo 4
Catania 4
Cleveland 4
Da Nang 4
Johannesburg 4
Las Vegas 4
Milwaukee 4
Mumbai 4
New Delhi 4
Omaha 4
Padua 4
Querétaro 4
Rio de Janeiro 4
Riyadh 4
San Francisco 4
Tianjin 4
Turin 4
Vinh 4
Athens 3
Brescia 3
Buenos Aires 3
Columbus 3
Eatonton 3
Greenville 3
Indianapolis 3
Ljubljana 3
Lucca 3
Modena 3
Nanning 3
Orlando 3
Pelotas 3
Pisa 3
Porto Alegre 3
Rochester 3
San José 3
Totale 2.582
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 446
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 438
Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models 188
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 168
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 163
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 148
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 145
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 142
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 142
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 138
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 136
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 135
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 131
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 128
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 123
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 119
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 119
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia 119
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 116
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 110
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 108
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 107
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 105
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 102
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 92
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 91
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 88
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice 85
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 83
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 83
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf: Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio 80
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 76
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 45
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study 29
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience 22
Tumor-targeted cytokine delivery by engineered myeloid cells unlocks CAR T cell efficacy and endogenous T cell responses in glioblastoma 21
Gene-based delivery of immune-activating cytokines for cancer treatment 15
null 7
Totale 4.593
Categoria #
all - tutte 12.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.345


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202316 2 3 0 2 2 1 1 0 2 3 0 0
2023/202442 0 1 5 2 5 4 0 0 0 2 8 15
2024/2025273 18 4 3 13 20 19 30 49 21 15 19 62
2025/20263.467 157 443 589 357 253 119 164 225 636 136 175 213
2026/2027794 168 148 160 318 0 0 0 0 0 0 0 0
Totale 4.593